Form 4: Maze Therapeutics Grants 40,000 RSUs to R&D President

Maze Therapeutics, Inc. granted 40,000 Restricted Stock Units to Harold Bernstein, President, R&D & CMO, as part of his compensation, vesting over two years.

Summary

• Harold Bernstein, President, R&D & CMO of Maze Therapeutics, Inc., was granted 40,000 Restricted Stock Units (RSUs).
• The transaction date for this grant was September 22, 2025.
• Each RSU represents a contingent right to receive one share of Maze Therapeutics' Common Stock upon settlement.
• The award will vest in two equal installments: 1/2 of the total award on September 1, 2026, and the remaining 1/2 on September 1, 2027.
• Vesting is contingent upon Mr. Bernstein's continued service to the Issuer on each respective vesting date.
• Following this transaction, Mr. Bernstein beneficially owns 40,000 derivative securities (RSUs).

Sentiment

Score: 6

Explanation: The grant of Restricted Stock Units is a standard compensation practice, generally viewed as a neutral to slightly positive event as it incentivizes executive retention and aligns management interests with shareholders, without indicating any immediate operational or financial performance changes.

Positives

• The RSU grant aligns the executive's interests with long-term shareholder value through equity ownership.
• It serves as an incentive for executive retention, requiring continued service for vesting over a two-year period.

Future Outlook

The vesting schedule for the Restricted Stock Units indicates an expectation of Harold Bernstein's continued service to Maze Therapeutics, Inc. through at least September 1, 2027, aligning his compensation with future company performance.

Industry Context

The grant of Restricted Stock Units is a common form of executive compensation in the biotechnology and pharmaceutical industries, used to attract, retain, and incentivize key talent by aligning their financial interests with the long-term success of the company.

Stakeholder Impact

• Shareholders: Potential minor dilution upon RSU settlement, but also increased alignment of executive incentives with long-term shareholder value.
• Employees: Reinforces the company's compensation structure for key executives.

Next Steps

• Harold Bernstein's continued service to Maze Therapeutics, Inc. through September 1, 2026, for the first tranche of RSU vesting.
• Harold Bernstein's continued service to Maze Therapeutics, Inc. through September 1, 2027, for the second tranche of RSU vesting.

Key Dates

Keywords

Restricted Stock Units, Executive Compensation, Insider Transaction, Maze Therapeutics, MAZE, Form 4, Equity Grant